Loading clinical trials...
Loading clinical trials...
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Conditions
Interventions
IMSA101
Immune checkpoint inhibitor (ICI)
+1 more
Locations
6
United States
Honor Health
Scottsdale, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Northwestern University
Chicago, Illinois, United States
Atlantic Health System/Morristown Medical Center
Morristown, New Jersey, United States
UT Southwestern
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
September 23, 2019
Primary Completion Date
September 15, 2023
Completion Date
September 15, 2023
Last Updated
December 11, 2024
NCT05223608
NCT06625775
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
ImmuneSensor Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions